

Original investigation

## **Abnormal breathlessness during cardiopulmonary exercise testing - validation in people with chronic airflow limitation**

Magnus Ekström, MD, PhD<sup>1,2</sup>, [magnus.ekstrom@med.lu.se](mailto:magnus.ekstrom@med.lu.se)

Pei Zhi Li, MSc<sup>3</sup>, [pei.li@mail.mcgill.ca](mailto:pei.li@mail.mcgill.ca)

Hayley Lewthwaite, PhD<sup>4,5</sup>, [hayley.lewthwaite@newcastle.edu.au](mailto:hayley.lewthwaite@newcastle.edu.au)

Jean Bourbeau, MD<sup>3,6</sup>, [jean.bourbeau@mcgill.ca](mailto:jean.bourbeau@mcgill.ca)

Wan C. Tan, MD<sup>7</sup>, [Wan.Tan@hli.ubc.ca](mailto:Wan.Tan@hli.ubc.ca)

Dennis Jensen, PhD<sup>2,6</sup>, [dennis.jensen@mcgill.ca](mailto:dennis.jensen@mcgill.ca)

On behalf of the CanCOLD Collaborative Research Group\*

1. Lund University, Faculty of Medicine, Department of Clinical Sciences Lund, Respiratory Medicine, Allergy and Palliative Medicine, Lund, Sweden
2. Clinical Exercise and Respiratory Physiology Laboratory, Department of Kinesiology and Physical Education, Faculty of Education, McGill University, Montréal, QC, Canada
3. Montreal Chest Institute, McGill University Health Center Research Institute, McGill University, Montréal, Québec, Canada
4. Centre of Research Excellence Treatable Traits, College of Medicine, Health and Wellbeing, University of Newcastle, Newcastle, NSW, Australia
5. Asthma and Breathing Research Program, Hunter Medical Research Institute, Newcastle, NSW, Australia
6. Research Institute of the McGill University Health Centre, Translational Research in Respiratory Diseases Program and Respiratory Epidemiology and Clinical Research Unit, Montréal, QC, Canada
7. University of British Columbia Centre for Heart Lung Innovation, Department of Medicine, Vancouver, BC, Canada

\*Please see Acknowledgements at the end of manuscript

**Corresponding author:** Magnus Ekström, Department of Medicine, Blekinge Hospital, SE-37185 Kalskrona, Sweden. Tel: +46(0)455731000; [magnus.ekstrom@med.lu.se](mailto:magnus.ekstrom@med.lu.se)

**Take home message:** Evaluation of the presence and level of abnormal exertional breathlessness during CPET using the first normative reference equations was valid in people with chronic airflow limitation.

**Conflict of interest:** JB and WT report receiving institutional funding for the CanCOLD study from Astra Zeneca Canada Ltd., Boehringer-Ingelheim Canada Ltd, GlaxoSmithKline Canada Ltd, Merck, Novartis Pharma Canada Inc., as well as Nycomed Canada Inc. (WT), Pfizer Canada Ltd. (WT), Trudell (JB), and Grifolds (JB). No conflicts of interest exist for any of the other authors.

**Running head:** Validation of breathlessness references during CPET

**Keywords:** dyspnea; exercise test; reference values; exercise capacity

**Number of tables:** 2; **Number of figures:** 2; **Number of references:** 40.

**This article has an online supplement.**

**Word count for body of text:** 3,006

**Word count for abstract:** 249

## ABSTRACT

**Background:** Exertional breathlessness is the cardinal symptom in cardiorespiratory disease.

We aimed to validate recently developed normative reference equations to evaluate breathlessness abnormality during cardiopulmonary exercise testing (CPET) in people with chronic airflow limitation.

**Methods:** Analysis of people aged  $\geq 40$  years with chronic airflow limitation undergoing CPET in the Canadian Cohort Obstructive Lung Disease (CanCOLD) study. Breathlessness intensity ratings (Borg 0-10 category ratio scale [CR10]) were evaluated in relation to power output ( $W$ ), rate of oxygen uptake ( $V'O_2$ ), and minute ventilation ( $V'E$ ) at peak exercise using normative reference equations as: 1) probability of breathlessness normality, defined as the predicted probability of the Borg CR10 rating among healthy references, with lower probability reflecting more severe breathlessness; and 2) presence of abnormal breathlessness, defined as a Borg CR10 intensity rating above the upper limit of normal (ULN). Validity of breathlessness severity (lower probability of normality) and abnormality ( $>ULN$ ) was evaluated as correlations with relevant participant-reported and physiologic outcomes.

**Results:** We included 330 participants (44% women): mean $\pm$ SD age 64 $\pm$ 10 years (range 40–89), FEV<sub>1</sub>/FVC 57.3 $\pm$ 8.2%, FEV<sub>1</sub> 75.6 $\pm$ 17.9% predicted. Relative to peak  $W$ ,  $V'O_2$  and  $V'E$ , abnormal breathlessness was present in 22.7%, 21.5%, and 15.2% of participants, respectively. For all equations, people with abnormal breathlessness had worse lung function, exercise capacity, self-reported symptom burden, physical activity, health-related quality of life, and physiological abnormalities during CPET.

**Conclusion:** Evaluation of breathlessness abnormality using CPET normative reference equations was valid in people with chronic airflow limitation.

## INTRODUCTION

Exertional breathlessness is a major distressing and limiting symptom in people with cardiopulmonary disease <sup>1</sup>. To avoid breathlessness, many people will reduce their physical activity and enter into a vicious circle of deconditioning and further worsening of breathlessness at progressively lower levels of exertion <sup>2</sup>. Given the impact of breathlessness on daily life, as well as its strong associations with adverse health outcomes including premature death <sup>3</sup>, breathlessness is a major treatment target in cardiopulmonary diseases <sup>4</sup>. To be able to detect abnormal breathlessness and quantify its severity and response to therapy, valid assessment of breathlessness at a standardized level exertion is key <sup>5,6</sup>.

Cardiopulmonary exercise testing (CPET) is the gold standard for assessing exertional breathlessness in clinical care and research <sup>6-8</sup>. Recently, normative reference equations were published for assessing abnormality of the breathlessness response to CPET, in relation to power output (W), rate of oxygen uptake ( $\dot{V}O_2$ ), and minute ventilation ( $\dot{V}_E$ ) <sup>9</sup>. Each of the physiologic variables (W,  $\dot{V}O_2$ ,  $\dot{V}_E$ ) can be analyzed as absolute values or percent of the person's predicted maximum value (%pred<sub>max</sub>). The normative reference equations can be used to calculate two key breathlessness measures: 1) *probability of breathlessness normality*, defined as the predicted probability of observing the person's Borg 0-10 category ratio scale (Borg CR10) breathlessness intensity rating among healthy people (reference population) with the same covariates (age, sex, body mass, and [W or  $\dot{V}O_2$  or  $\dot{V}_E$ ]), where a lower probability means that the intensity rating is less likely among healthy and, thus, reflects more abnormal (or severe) exertional breathlessness; and 2) *presence of abnormal breathlessness*, defined as a Borg CR10 intensity rating above the person's predicted upper limit of normal (ULN) <sup>9</sup>.

The objective of this study was to, for the first time, validate the normative reference equations of exertional breathlessness intensity in people with chronic airflow limitation. The specific objective was to test the hypothesis that (i) probability of breathlessness normality

and (ii) presence of abnormal breathlessness ( $>ULN$ ) at the symptom-limited peak of incremental cycle CPET would differ by severity of airflow limitation (discriminant validity) and correlate with relevant outcomes (concurrent validity), including lung function, self-reported symptom burden and physical activity, health-related quality of life (HrQoL), exercise capacity, and exercise physiologic abnormalities mechanistically linked to exertional breathlessness<sup>10-14</sup>.

## **MATERIAL AND METHODS**

### **Study design and population**

This was an analysis of the Canadian Cohort Obstructive Lung Disease (CanCOLD) study<sup>15</sup>. CanCOLD is a prospective, population-based study conducted across nine communities in Canada (ClinicalTrials.gov Identifier: NCT00920348) of noninstitutionalized people aged  $\geq 40$  years originally identified through random telephone digit dialing<sup>15</sup>. All participants provided written informed consent prior to completing study assessments. The research ethics board for each participating institution approved the study protocol: UBC/ PHC Research Ethics Board, P05-006 (Vancouver); Biomedical-C Research Ethics Board, BMC-06-002 (Montreal); UHN REB, 06-0421-B (Toronto); Capital Health Research Ethics Board, CDHA-RS/2007-255 (Halifax); Conjoint Health Research Ethics Board, ID21258 (Calgary); DMED-1240-09 (Kingston); 2009519-01H (Ottawa); Bio-REB09-162 (Saskatoon); CER20459 (Quebec City).

This study is reported in accordance with the STrengthening the Reporting of OBServational studies in Epidemiology (STROBE) statement<sup>16</sup>.

CanCOLD participants were included in the current study if they had: 1) chronic airflow limitation defined as a post-bronchodilator forced expired volume in 1-s to forced vital capacity ratio (FEV<sub>1</sub>/FVC) below the predicted lower limit of normal (< LLN)<sup>17,18</sup>; 2) completed a symptom-limited incremental cycle CPET at visit 1 (baseline), without premature cessation of exercise due to a supervising physician determined adverse event or protocol error; and 3) provided an intensity rating of their perceived breathlessness at peak exercise (**Figure 1**).

### **Assessments and procedures**

All data were from CanCOLD visit 1. Participants self-reported socio-demographics and health information (e.g., smoking history and presence of physician-diagnosed health conditions) *via* structured interview with a trained researcher, whereas HrQoL was assessed using the Saint George's Respiratory Questionnaire (SGRQ)<sup>19</sup> and COPD Assessment Test (CAT)<sup>20</sup>. Impact of breathlessness on daily life activity was assessed using the Medical Research Council (MRC) 1–5 scale<sup>21</sup>. Physical activity was self-reported using the Community Healthy Activities Model Program for Seniors (CHAMPS) questionnaire<sup>22</sup>. Spirometry (post-bronchodilator), diffusing capacity of the lungs for carbon monoxide (D<sub>L</sub>CO), and plethysmographic lung volumes were assessed using automated equipment in accordance with ATS/ERS standards<sup>15,17,23</sup>. Predicted lung function values were calculated using Global Lung Function Initiative (GLI) references<sup>24-26</sup>. Severity of airflow limitation was categorized based on post-bronchodilator FEV<sub>1</sub>% predicted according to Global Initiative for Obstructive Lung Disease (GOLD) criteria: GOLD stage 1 (≥80%); GOLD stage 2 (50-79%); GOLD stage 3 (30-49%); and GOLD stage 4 (<30%)<sup>4</sup>.

### *Cardiopulmonary exercise testing (CPET)*

CPET was performed in accordance with recognized guidelines on an electronically braked cycle ergometer using a computerized CPET system<sup>27</sup>. The CPET protocol was standardized across sites, and included a steady state pre-exercise baseline period of three to 10 minutes, followed by one minute of unloaded pedalling, and then a 10 W/min increase in power output (starting at 10 W) until symptom limitation. Participants were encouraged to maintain a pedal cadence of 50-70 rpm, and testing was stopped if pedal cadence fell below 40 rpm.

Gas exchange and breathing pattern parameters were collected breath-by-breath with participants breathing through a mouthpiece and flow transducer while wearing a nose clip. Heart rate (HR) and rhythm were assessed continuously by 12-lead ECG, and peripheral oxyhemoglobin saturation (SpO<sub>2</sub>) was monitored by finger pulse oximetry. At rest, every two minutes during exercise, and at peak exercise, blood pressure was assessed, and participants performed maximal voluntary inspiratory capacity (IC) maneuvers<sup>28</sup>, and rated the intensity (magnitude) of their perceived breathlessness and leg discomfort using the modified Borg 0-10 category ratio (CR10) scale<sup>29</sup>. Prior to CPET, breathlessness was defined for each participant as “breathing discomfort” and leg discomfort as “the level of discomfort experienced during pedalling”; and participants were familiarized with Borg’s CR10 scale such that “0” represented “no breathing (leg) discomfort” and “10” represented “the most severe breathing (leg) discomfort that you have ever experienced or can imagine experiencing”.

### *Analysis of breathlessness responses*

Abnormality of breathlessness was evaluated using published CanCOLD normative reference equations in relation to peak W, V’O<sub>2</sub>, and V’<sub>E</sub>, respectively<sup>9</sup>. Peak W was taken as the highest power output a participant was able to sustain for ≥30-s, whereas peak V’O<sub>2</sub> and V’<sub>E</sub> were taken as the average of the last 30-s of loaded pedalling.

Using each of the three normative reference equations, the *probability of breathlessness normality* was defined as the predicted probability of each participant's Borg CR10 breathlessness intensity rating at peak exercise <sup>9</sup>. This probability reflects how likely each participant's breathlessness intensity rating would be at any given peak  $\dot{W}$ ,  $\dot{V}'O_2$ , and  $\dot{V}'_E$  relative to a healthy reference with similar age, sex and body mass, where a lower probability reflects a more abnormal (or severe) exertional breathlessness response <sup>9</sup>. For example, a predicted probability of 0.001 would indicate that less than 1/1,000 healthy people (with similar age, sex, and body mass) would report this or a higher breathlessness intensity rating. The *presence of abnormal exertional breathlessness* was categorized as a Borg CR10 breathlessness intensity rating at peak exercise  $> \text{ULN}$ , which corresponds to a probability  $< 0.05$  <sup>9</sup>.

#### *Analysis of physiological responses to CPET*

Physiological variables evaluated in the current study included:

- Exercise capacity as peak  $\dot{W}$  and  $\dot{V}'O_2$ ;
- Change in IC from pre-exercise baseline to peak exercise expressed in litres ( $\Delta \text{IC}$ ) and indexed to peak  $\dot{V}'_E$  ( $\Delta \text{IC}/\dot{V}'_E$ );
- Proportion of people with clinically significant dynamic hyperinflation, defined as decrease in IC  $> 0.15\text{L}$  from pre-exercise baseline to peak exercise <sup>30</sup>;
- Nadir of the ventilatory equivalent for carbon dioxide ( $\dot{V}'_E/\dot{V}'CO_2$ ), identified as the lowest 30-s average data point observed during CPET;
- Proportion of people with exercise ventilatory inefficiency, defined as nadir  $\dot{V}'_E/\dot{V}'CO_2 > \text{ULN}$ , and  $>34$  <sup>31</sup>; and
- Critical inspiratory constraints as the (i) tidal volume-to-inspiratory capacity ratio ( $V_T\% \text{IC}$ ) and (ii) end-inspiratory lung volume-to-total lung capacity ratio



(EILV% TLC), with both ratios indexed to peak  $V'_E$  ( $V_T\%IC/V'_E$  and  $EILV\%TLC/V'_E$ ).

Unless indicated otherwise, all physiological variables and Borg CR10 breathlessness intensity ratings used in the analyses were values at peak exercise, to have a common point of assessment for comparisons. Predicted values for the physiological parameters at the symptom-limited peak of CPET were calculated using CanCOLD normative reference equations <sup>31</sup>.

### **Statistical analyses**

Participant characteristics and outcome variables (self-reported and physiological variables) were summarized using mean with standard deviation (SD) and median with range or interquartile range (IQR) for continuous variables, as appropriate. Categorical variables were expressed as frequencies and percentages. No data were imputed.

Discriminant validity of the predicted probability of breathlessness normality was analyzed by plotting the relationship between the predicted probability (categorized as: 0.74-0.50; 0.49-0.25; 0.24-0.05; and  $< 0.05$ ) and each outcome variable with 95% confidence intervals (CIs).

Discriminant validity of the presence of abnormal exertional breathlessness ( $>ULN$ ) vs. normal exertional breathlessness ( $\leq ULN$ ) was analyzed as the between-group difference in each outcome, using Student's t-tests and Wilcoxon-Mann-Whitney test for continuous and Chi-square and Fishers exact test for categorical variables. To assess concurrent validity, correlations between abnormal breathlessness and each outcome was analyzed as point biserial correlations <sup>32</sup>. All analyses were performed using each normative reference equation (one for each of  $W$ ,  $V'O_2$ , and  $V'_E$ ).

Statistical significance was defined as two-sided p-value < 0.05. Statistical analyses were conducted using the SAS version 9.4 software (TS1M5) (SAS Institute Inc., Cary, NC, USA, 2016).

## RESULTS

A total of 330 participants (44% women) with chronic airflow limitation were included (**Figure 1**). Participants had a mean age of 64.4 (SD 10.2) years and BMI of 27.2 kg/m<sup>2</sup> (SD 4.9). The majority of participants: were relatively asymptomatic (10% and 39.4% had MRC breathlessness rating  $\geq 3$  and CAT total score  $\geq 10$ , respectively); had only mild to moderate airflow chronic limitation (41% had GOLD stage 1, and 51% GOLD stage 2); did not have a prior physician-diagnosis of COPD (38.5%); and were not taking any respiratory medication(s) at the time of CanCOLD visit 1 (49.7%) (**Table 1**).

### Probability of breathlessness normality

The distribution of predicted probabilities for the peak breathlessness intensity ratings relative to W, V'O<sub>2</sub> and V'E are shown in **Figure S1**. A lower probability of breathlessness normality (reflecting more abnormal [or severe] exertional breathlessness) was related to having worse outcomes, including: lower lung function; greater self-reported symptom burden; lower self-reported physical activity; lower HrQoL; lower exercise capacity; and more severe physiological abnormalities at peak exercise (**Figure 2**).

### Presence of abnormal breathlessness

The prevalence of abnormal breathlessness (Borg CR10 breathlessness intensity rating > ULN) at peak exercise was 22.7% in relation to W, 21.5% in relation to V'O<sub>2</sub>, and 15.2% in

relation to  $V'_E$  (**Table 2**). Overlap between the categorizations of abnormal breathlessness using the different equations is shown in **Figure S2**. Almost all participants with abnormal breathlessness in relation to  $V'_E$  were also abnormal in relation to  $V'O_2$ , with very few ( $n=4$ ) participants abnormal relative to  $V'_E$  only.

*Discriminative validity:* For all three normative reference equations, people with abnormal vs. normal exertional breathlessness presented with: more severe chronic airflow limitation (lower  $FEV_1/FVC$ ); worse lung function (lower  $FEV_1$ ,  $FVC$  and  $D_LCO$  %predicted); higher respiratory symptom burden (higher  $MRC$ ,  $CAT$  and  $SGRQ$  scores); lower self-reported physical activity; greater exercise intolerance (lower peak  $W$  and  $V'O_2$ ); and more severe critical inspiratory constraints at peak exercise (higher  $V_T\%IC/V'_E$  and  $EILV\%TLC/V'_E$ ) (**Table 2**). In addition, for reference equations using  $W$  and  $V'O_2$  (but not  $V'_E$ ), people with abnormal vs. normal exertional breathlessness presented with more prevalent and severe exercise ventilatory inefficiency (higher nadir  $V'_E/V'CO_2$ ; and greater proportion of people with nadir  $V'_E/V'CO_2 > 34$  or  $>ULN$ ) (**Table 2**).

*Concurrent validity:* With few exceptions, the correlations between abnormal exertional breathlessness and the outcomes were similar when using the different normative reference equations (**Table S1**). In contrast to abnormal exertional breathlessness in relation to peak  $W$  or  $V'O_2$ , having abnormal exertional breathlessness in relation to peak  $V'_E$  was not correlated with  $D_LCO$  (% predicted), peak  $W$  (% predicted) or nadir  $V'_E/V'CO_2$  (**Table 2**, **Table S1**).

## DISCUSSION

This is the first validation of the CPET normative reference equations<sup>9</sup> for exertional breathlessness intensity in people with chronic airflow limitation. The main findings are that exertional breathlessness measured as i) the probability of breathlessness normality at peak

exercise, and ii) presence of abnormal breathlessness at peak exercise showed discriminative validity by severity of airflow limitation and exercise intolerance, and concurrent validity with other relevant participant-reported and physiological outcomes. In our sample of relatively asymptomatic older adults with mostly mild-to-moderate chronic airflow limitation, people with abnormal breathlessness on CPET had worse lung function, lower exercise capacity, greater respiratory symptom burden, lower self-reported physical activity, and worse HrQoL.

Due to the population-based design, CanCOLD includes a high proportion of relatively healthy participants, with only mild airflow limitation, undiagnosed respiratory disease, no respiratory medication, and no or low burden of self-reported symptoms in daily life<sup>9,15</sup>. This is likely to explain the relatively low prevalence (<25%) of abnormal breathlessness in this sample. As detection of symptoms is particularly challenging in healthier, asymptomatic populations (in contrast to in people with established, more severe disease), this makes CanCOLD particularly informative for evaluating the validity of methods for breathlessness assessment.

Supporting the validity of the CPET normative reference equations, people with abnormal exertional breathlessness (compared to those with breathlessness within normal ranges) had greater underlying exercise physiological abnormalities known to contribute to exertional breathlessness<sup>8</sup>. Specifically, people with abnormal *vs.* normal exertional breathlessness in relation to both peak  $\dot{W}$  and  $\dot{V}'O_2$  presented with greater exercise ventilatory inefficiency (higher nadir  $\dot{V}'_E/\dot{V}'CO_2$ ) and greater critical inspiratory constraints (higher  $V_T\%IC/\dot{V}'_E$  and  $EILV\%TLC/\dot{V}'_E$ ) at peak exercise, whereas people with abnormal *vs.* normal exertional breathlessness in relation to peak  $\dot{V}'_E$  did not have greater exercise ventilatory inefficiency but did present with greater critical inspiratory constraints at peak exercise.

Taken together, the results support that the CPET normative reference equations<sup>9</sup> are valid for categorizing the presence and level of abnormal exertional breathlessness in people with chronic airflow limitation. These findings have several important implications. First, they reinforce the use of CPET as the gold standard method to evaluate exertional breathlessness in terms of underlying mechanisms, treatment effects<sup>8,33-35</sup>, and also the presence and level of abnormal exertional breathlessness. Second, the CPET normative reference equations provide the first valid benchmark for defining abnormal exertional breathlessness. Abnormal breathlessness during CPET can be used to evaluate and compare different ways of assessing breathlessness and/or respiratory symptom burden such as task-based questionnaires like MRC and CAT; to select participants for clinical (therapeutic) trials based on the presence and/or level of abnormal exertional breathlessness. The current practice to determine breathlessness severity and trial eligibility using questionnaires such as the modified MRC is limited by misinterpretation<sup>36,37</sup>, misclassification<sup>38</sup>, and failure to evaluate breathlessness at a standardized level of exertion or ventilation, which may lead to breathlessness being underreported or hidden in people who have restricted their physical activity to avoid undue breathlessness<sup>5,39</sup>. These problems are likely to be overcome by categorizing the level of exertional breathlessness using CPET<sup>39,40</sup>. Third, we have validated all three normative reference equations to use when evaluating an individual's exertional breathlessness response – in relation to  $\dot{W}$ ,  $\dot{V}'O_2$  and  $\dot{V}'_E$ . In line with our current understanding of the pathophysiological mechanisms of exertional breathlessness in people with chronic airflow limitation<sup>8</sup>, breathlessness intensity ratings that were abnormal in relation to peak  $\dot{W}$  and/or  $\dot{V}'O_2$  were accompanied by evidence of (i) more prevalent and severe exercise ventilatory inefficiency and (ii) more severe critical inspiratory constraints, whereas breathlessness intensity ratings that were abnormal in relation to peak  $\dot{V}'_E$  were associated with more severe critical inspiratory constraints only. An intriguing next step is to see if an individual's profile

of exertional breathlessness abnormality (by  $V'_E$  and/or  $V'O_2$ ) might help to identify the underlying physiological mechanism(s) contributing to abnormal exertional breathlessness in clinical practice.

*Which of the different reference equations should be used to evaluate the (ab)normality of exertional breathlessness?* Based on the present findings, we suggest that evaluation of exertional breathlessness in relation to both peak  $V'O_2$  and peak  $V'_E$  should be the first line option in most situations. This is based on the high degree of overlap between categorization exertional breathlessness by peak W and peak  $V'O_2$  (both measures of exercise intensity or level of exertion), and that the equation by peak  $V'O_2$  identified all participants who were also abnormal by peak  $V'_E$ . Defining abnormal exertional breathlessness using reference equations for both peak W and peak  $V'O_2$  could, however, identify some additional people as having abnormal exertional breathlessness. The cross-talk between the different reference equations to categorize the (ab)normality of exertional breathlessness needs to be further explored.

Strengths of this study is the multicenter, population-based design, which reduces the risk of selection bias; the wide range of relevant outcome measures, including self-reported respiratory symptom burden and HrQoL using validated questionnaires (MRC, CAT, SGRQ), lung function (spirometry, plethysmography,  $D_LCO$ ), and detailed physiological outcomes assessed during symptom-limited incremental cycle CPET – a breadth of factors unique to the CanCOLD dataset<sup>15</sup> and that are optimal for demonstrating both the discriminative and concurrent validity of the CPET normative reference equations for exertional breathlessness<sup>9</sup>.

Next research steps include validating the normative reference equations in people with more severe chronic airflow limitation, and in other chronic health conditions such as interstitial lung disease and heart disease. Further research possibilities include: evaluating the prevalence of abnormal exertional breathlessness across populations and patient groups; defining the method's responsiveness and minimal clinically important difference; and to

evaluate the prognostic implication of abnormal exertional breathlessness on clinical outcomes and risk of premature death.

In conclusion, evaluation of the presence and level of abnormal breathlessness using CPET normative reference equations (in relation to peak  $\dot{W}$ ,  $\dot{V}'O_2$ , or  $\dot{V}'_E$ ) showed discriminative and concurrent validity in relation to other relevant clinical and patient-reported outcomes, including lung function, respiratory symptom burden, self-reported physical activity, HrQoL, exercise capacity, and underlying exercise physiologic abnormalities among people with chronic airflow limitation. Through use of these normative reference equations, researchers and clinicians can, for the first time, evaluate the presence and quantify the level of abnormally high exertional breathlessness, in patient groups or in the individual.

**Acknowledgments:** The authors thank the people who participated in the study and the many members of the CanCOLD collaborative research group: **Executive Committee:** Jean Bourbeau (McGill University, Montreal, QC, Canada); Wan C Tan, J Mark FitzGerald, Don D Sin (University of British Columbia, Vancouver, BC, Canada); Darcy D Marciniuk (University of Saskatoon, Saskatoon, SK, Canada); Denis E O'Donnell (Queen's University, Kingston, ON, Canada); Paul Hernandez (Dalhousie University, Halifax, NS, Canada); Kenneth R Chapman (University of Toronto, Toronto, ON, Canada); Brandie Walker (University of Calgary, Calgary, AB, Canada); Shawn Aaron (University of Ottawa, Ottawa, ON, Canada); François Maltais (University of Laval, Quebec City, QC, Canada).

**International Advisory Board:** Jonathon Samet (the Keck School of Medicine of USC, California, USA); Milo Puhan (John Hopkins School of Public Health, Baltimore, USA); Qutayba Hamid (McGill University, Montreal, QC, Canada); James C Hogg (University of British Columbia, Vancouver, BC, Canada). **Operations Center:** Jean Bourbeau (Principal Investigator), Dany Doiron, Palmira Mancino, Pei Zhi Li, Dennis Jensen, Carolyn Baglole (McGill University, Montreal, QC, Canada); Yvan Fortier (Laboratoire telematique, Quebec Respiratory Health Network, Fonds de la recherche en santé du Québec (FRQS)); Wan C Tan (co-Principal Investigator), Don Sin, Julia Yang, Jeremy Road, Joe Comeau, Adrian Png, Kyle Johnson, Harvey Coxson, Jonathon Leipsic, Cameron Hague (University of British Columbia, Vancouver, BC, Canada), Miranda Kirby (Ryerson University, Toronto, ON, Canada) **Economic Core:** Mohsen Sadatsafavi (University of British Columbia, Vancouver, BC, Canada). **Public Health Core:** Teresa To, Andrea Gershon (University of Toronto, Toronto, ON, Canada). **Data management and Quality Control:** Wan C Tan, Harvey Coxson (University of British Columbia, Vancouver, BC, Canada); Jean Bourbeau, Pei-Zhi Li, Zhi Song, Andrea Benedetti, Dennis Jensen (McGill University, Montreal, QC, Canada); Yvan Fortier (Laboratoire telematique, Quebec Respiratory Health Network, FRQS); Miranda



Kirby (Ryerson University, Toronto, ON, Canada). **Field Centers:** Wan C Tan (Principal Investigator), Christine Lo, Sarah Cheng, Elena Un, Cynthia Fung, Wen Tiang Wang, Liyun Zheng, Faize Faroon, Olga Radivojevic, Sally Chung, Carl Zou (University of British Columbia, Vancouver, BC, Canada); Jean Bourbeau (Principal Investigator), Palmina Mancino, Jacinthe Baril, Laura Labonte (McGill University, Montreal, QC, Canada); Kenneth Chapman (Principal Investigator), Patricia McClean, Nadeen Audisho (University of Toronto, Toronto, ON, Canada); Brandie Walker (Principal Investigator), Curtis Dumonceaux, Lisette Machado (University of Calgary, Calgary, AB, Canada); Paul Hernandez (Principal Investigator), Scott Fulton, Kristen Osterling, Denise Wigerius (University of Halifax, Halifax, NS, Canada); Shawn Aaron (Principal Investigator), Kathy Vandemheen, Gay Pratt, Amanda Bergeron (University of Ottawa, Ottawa, ON, Canada); Denis O'Donnell (Principal Investigator), Matthew McNeil, Kate Whelan (Queen's University, Kingston, ON, Canada); François Maltais (Principal Investigator), Cynthia Brouillard (University of Laval, Quebec City, QC, Canada); Darcy Marciniuk (Principal Investigator), Ron Clemens, Janet Baran, Candice Leuschen (University of Saskatoon, Saskatoon, SK, Canada).

**Funding:** The CanCOLD study (ClinicalTrials.gov Identifier: NCT00920348) has received support from the Canadian Respiratory Research Network, the Canadian Institutes of Health Research [CIHR/Rx&D Collaborative Research Program Operating Grant 93326], the Respiratory Health Research Network of the Fonds de la Recherche en Santé du Québec, the Foundation of the McGill University Health Centre and industry partners, including: AstraZeneca Canada Ltd., Boehringer Ingelheim Canada Ltd., GlaxoSmithKline (GSK) Canada Ltd., Novartis, Almirall, Merck, Nycomed, Pfizer Canada Ltd., and Theratechnologies. ME is supported by unrestricted grants from the Swedish Society for Medical Research and the Swedish Research Council (Dnr 2019-02081). HL is supported by a

postdoctoral research fellowship from the National Health and Medical Research Council  
Centre of Research Excellence in Treatable Traits. DJ holds a Canada Research Chair, Tier II,  
in Clinical Exercise & Respiratory Physiology from the Canadian Institutes of Health  
Research.

**Role of the funders:** The funders had no role in any aspect of the article.

**Author contributions statement:** Study conception and design (ME, HL, DJ); data  
collection (JB, WCT, DJ); statistical analysis (PZL); first draft (ME); interpretation, revision  
the manuscript for intellectual contents, and approval of the final version to submit (all  
authors).

## REFERENCES

- 1 Sundh J, Ekström M. Persistent disabling breathlessness in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis* 2016; 11:2805-2812
- 2 Ramon MA, Ter Riet G, Carsin AE, et al. The dyspnoea-inactivity vicious circle in COPD: development and external validation of a conceptual model. *Eur Respir J* 2018; 52
- 3 Sandberg J, Engstrom G, Ekstrom M. Breathlessness and incidence of COPD, cardiac events and all-cause mortality: A 44-year follow-up from middle age throughout life. *PLoS One* 2019; 14:e0214083
- 4 From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. Available from: <http://goldcopd.org/> [Accessed 26-12-2022].
- 5 Lewthwaite H, Koch EM, Tracey L, et al. Standardized measurement of breathlessness during exercise. *Curr Opin Support Palliat Care* 2019; 13:152-160
- 6 Lewthwaite H, Jensen D, Ekström M. How to Assess Breathlessness in Chronic Obstructive Pulmonary Disease. *Int J Chron Obstruct Pulmon Dis* 2021; 16:1581-1598
- 7 Bonini M, Fiorenzano G. Exertional dyspnoea in interstitial lung diseases: the clinical utility of cardiopulmonary exercise testing. *European Respiratory Review* 2017; 26:160099
- 8 Stickland MK, Neder JA, Guenette JA, et al. Using Cardiopulmonary Exercise Testing to Understand Dyspnea and Exercise Intolerance in Respiratory Disease. *Chest* 2022; 161:1505-1516
- 9 Ekström M, Li PZ, Lewthwaite H, Bourbeau J, Tan WC, Schiöler L, Brotto A, Stickland MK, Jensen D. Normative reference equations for breathlessness intensity during incremental cardiopulmonary cycle exercise testing in people aged 40 years and older. *Annals of the American Thoracic Society* 2023. *In press*.
- 10 Neder JA, Marillier M, Bernard A-C, et al. Transfer coefficient of the lung for carbon monoxide and the accessible alveolar volume: clinically useful if used wisely. *Breathe* 2019; 15:69
- 11 Lewthwaite H, Li PZ, O'Donnell DE, et al. Multidimensional breathlessness response to exercise: Impact of COPD and healthy ageing. *Respir Physiol Neurobiol* 2021; 287:103619
- 12 O'Donnell DE, Ora J, Webb KA, et al. Mechanisms of activity-related dyspnea in pulmonary diseases. *Respir Physiol Neurobiol* 2009; 167:116-132
- 13 O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. *Am J Respir Crit Care Med* 1997; 155:109-115
- 14 Laveneziana P, Webb KA, Ora J, et al. Evolution of Dyspnea during Exercise in Chronic Obstructive Pulmonary Disease. *Am J Respir Crit Care Med* 2011; 184:1367-1373
- 15 Bourbeau J, Tan WC, Benedetti A, et al. Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the need for longitudinal observational studies in COPD. *COPD* 2014; 11:125-132
- 16 Elm Ev, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* 2007; 335:806
- 17 Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* 2022; 60
- 18 Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40:1324-1343
- 19 Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. *Am Rev Respir Dis* 1992; 145:1321-1327
- 20 Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. *Eur Respir J* 2009; 34:648-654

- 21 Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. *Thorax* 1999; 54:581-586
- 22 Stewart AL, Mills KM, King AC, et al. CHAMPS physical activity questionnaire for older adults: outcomes for interventions. *Med Sci Sports Exerc* 2001; 33:1126-1141
- 23 ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003; 167:211-277
- 24 Hall GL, Filipow N, Ruppel G, et al. Official ERS technical standard: Global Lung Function Initiative reference values for static lung volumes in individuals of European ancestry. *Eur Respir J* 2021; 57
- 25 Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. *Eur Respir J* 2017; 50
- 26 Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. *Eur Respir J* 2012; 40:1324-1343
- 27 American Thoracic S, American College of Chest P. ATS/ACCP Statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med* 2003; 167:211-277
- 28 Guenette JA, Chin RC, Cory JM, et al. Inspiratory Capacity during Exercise: Measurement, Analysis, and Interpretation. *Pulm Med* 2013; 2013:956081
- 29 Burdon JG, Juniper EF, Killian KJ, et al. The perception of breathlessness in asthma. *Am Rev Respir Dis* 1982; 126:825-828
- 30 Radtke T, Crook S, Kaltsakas G, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. *Eur Respir Rev* 2019; 28:180101
- 31 Lewthwaite H, Benedetti A, Stickland MK, et al. Normative Peak Cardiopulmonary Exercise Test Responses in Canadian Adults Aged  $\geq 40$  Years. *Chest* 2020; 158:2532-2545
- 32 Glass GV, Hopkins KD. *Statistical Methods in Education and Psychology* (3rd ed.) 1995. Allyn & Bacon. ISBN 0-205-14212-5. .
- 33 Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. *Eur Respir J* 2016; 47:429-460
- 34 Ekström M. Tests to uncover and assess breathlessness: a proposed framework. *Current Opinion in Supportive and Palliative Care* 2022; 16:188-194
- 35 Radtke T, Crook S, Kaltsakas G, et al. ERS statement on standardisation of cardiopulmonary exercise testing in chronic lung diseases. *European Respiratory Review* 2019; 28:180101
- 36 Sunjaya A, Poulos L, Reddel H, et al. Qualitative validation of the modified Medical Research Council (mMRC) dyspnoea scale as a patient-reported measure of breathlessness severity. *Respir Med* 2022
- 37 Yorke J, Khan N, Garrow A, et al. Evaluation of the Individual Activity Descriptors of the mMRC Breathlessness Scale: A Mixed Method Study. *Int J Chron Obstruct Pulmon Dis* 2022; 17:2289-2299
- 38 Ekström M, Chang S, Johnson MJ, et al. Low agreement between mMRC rated by patients and clinicians: implications for practice. *Eur Respir J* 2019; 54
- 39 Ekstrom M, Elmberg V, Lindow T, et al. Breathlessness measurement should be standardised for the level of exertion. *Eur Respir J* 2018; 51
- 40 Elmberg V, Schiöler L, Lindow T, Hedman K, Malinovsky A, Lewthwaite H, Jensen D, Brudin L, Ekström M. Reference equations for breathlessness during incremental cycle exercise testing. *ERJ Open Research* 2022. *In press*.

## TABLES

**Table 1.** Participant characteristics

<b>Characteristic</b>	<b>All (n=330)</b>
Age, years, mean (SD) [min, max]	64.4 (10.2), 64.0 (40.0, 89.0)
Women, n (%)	145 (43.9)
Body mass, kg	77.9 (16.3)
Body mass index, kg/m <sup>2</sup>	27.2 (4.9)
Cigarette smoking status, n (%)	
Never smoker	93 (28.2)
Former smoker	165 (50.0)
Current smoker	72 (21.8)
Cigarette smoker pack-years	25.8 (24.9)
Hypertension, n (%)	104 (31.5)
Physician-diagnosed COPD, n (%)	127 (38.5)
Physician-diagnosed asthma, n (%)	139 (42.1)
Any respiratory medication(s), n (%)	164 (49.7)
MRC breathlessness rating	1.7 (0.7)
1, n (%)	150 (45.5)
2, n (%)	136 (41.2)
≥3, n (%)	33 (10.0)
HADS anxiety score	4.0 (3.1)
HADS depression score	2.9 (2.7)
CAT	8.9 (6.8)
CAT≥10, n (%)	130 (39.4)
SGRQ-Total score	18.5 (16.1)
CHAMPS moderate and greater intensity, Caloric expenditure per week (KC)	2330.9 (2452.3)
CHAMPS all activities, Caloric expenditure per week (KC)	4093.8 (2983.7)
<b>Lung function</b>	
FEV <sub>1</sub> , %pred	75.6 (17.9)
GOLD stage, n (%)	
GOLD 1 (FEV <sub>1</sub> /FVC <0.7 and FEV <sub>1</sub> ≥ 80% predicted)	135 (40.9)
GOLD 2 (FEV <sub>1</sub> /FVC <0.7 and FEV <sub>1</sub> ≥ 50% and < 80% predicted)	167 (50.6)
GOLD 3 (FEV <sub>1</sub> /FVC <0.7 and FEV <sub>1</sub> ≥ 30% and < 50% predicted)	27 (8.2)
GOLD 4 (FEV <sub>1</sub> /FVC <0.7 and FEV <sub>1</sub> < 30% predicted)	1 (0.3)
FVC, %pred	102.1 (19.4)
FEV <sub>1</sub> /FVC, %	57.3 (8.2)
TLC, %pred	110.2 (15.3)
IC, %pred	95.1 (22.7)
D <sub>L</sub> CO, %pred	87.9 (23.5)
<b>Symptom-limited peak CPET parameters</b>	
Power output (W), %pred	81.5 (25.2)
V'O <sub>2</sub> , %pred	82.7 (23.1)
V'E, %pred	83.5 (24.7)
Nadir V'E/V'CO <sub>2</sub>	32.0 (6.7)
V'E/V'CO <sub>2</sub> nadir > 34, n (%)	100 (30.4)

$V'_E/V'CO_2$ nadir > ULN, n (%)	76 (23.1)
$V_T\%IC/V'_E$	1.41 (0.53)
EILV%TLC/ $V'_E$	1.81 (0.73)
$\Delta IC$ (L)	-0.22 (0.39)
Decrease in IC > 0.15L from baseline to peak exercise, n (%)	173 (56.0)
$\Delta IC/V'_E$	-0.004 (0.009)
Breathlessness (Borg CR10), median (Q1, Q3)	5.0 (4.0,7.0)
Leg discomfort (Borg CR10), median (Q1, Q3)	7.0 (4.0,8.0)

Data presented as mean (standard deviation) unless otherwise specified.

*Abbreviations:* CAT = COPD Assessment Test; CHAMPS = Community Healthy Activities Model Program for Seniors questionnaire; COPD = chronic obstructive pulmonary disease; CR = category-ratio; DBP = diastolic blood pressure;  $D_LCO$  = diffusion lung capacity for carbon monoxide; EILV = end-inspiratory lung volume;  $FEV_1$  = forced expired volume in one second; FVC = forced vital capacity; GOLD = Global Initiative for Obstructive Lung Disease; HADS = Hospital Anxiety and Depression Scale; HR = heart rate; IC = inspiratory capacity; MRC = Medical Research Council; RER = respiratory exchange ratio; RV = residual volume; SBP = systolic blood pressure; SD = standard deviation; SGRQ = Saint George's Respiratory Questionnaire;  $SpO_2$  = peripheral saturation of oxygen; TLC = total lung capacity; Q = quartile;  $V'CO_2$  = rate of exhaled carbon dioxide;  $V'_E$  = minute ventilation;  $V'O_2$  = rate of oxygen uptake;  $V_T$  = tidal volume; W = watt;  $\Delta$  = change from baseline to peak exercise.

**Table 2.** Outcomes in people with abnormal vs. normal breathlessness at the symptom-limited peak of incremental cardiopulmonary cycle exercise testing

	Breathlessness intensity evaluated using normative reference equations in relation to								
	Peak W			Peak V'O <sub>2</sub>			Peak V'E		
	Abnormal	Normal	P-value	Abnormal	Normal	P-value	Abnormal	Normal	P-value
	n=75 (22.7%)	n=255 (77.2%)		n=71 (21.5%)	n=259 (78.5%)		n=50 (15.2%)	n=280 (84.8%)	
Age, years, mean (SD) [min, max]	67.4 (11.1), [40.0, 89.0]	63.5 (9.7), [40.0, 87.0]	0.003*	69.3 (10.1), [40.0, 89.0]	63.0 (9.8), [40.0, 87.0]	<0.001*	68.3 (10.9), [40.0, 89.0]	63.7 (9.9), [40.0, 87.0]	0.003*
Women, n (%)	30 (40.0)	115 (45.1)	0.434	33 (46.5)	112 (43.2)	0.626	28 (56.0)	117 (41.8)	0.062
Body mass, kg	77.1 (15.6)	78.1 (16.5)	0.558	76.0 (15.2)	78.4 (16.6)	0.252	76.9 (15.5)	78.1 (16.5)	0.472
Body mass index, kg/m <sup>2</sup>	27.6 (5.6)	27.0 (4.7)	0.564	27.5 (5.7)	27.1 (4.7)	0.954	28.4 (5.7)	26.9 (4.7)	0.195
Cigarette smoking status, n (%)									
Never smoker	15 (20.0)	78 (30.6)	0.073	15 (20.0)	78 (30.6)	0.073	12 (24.0)	81 (28.9)	0.476
Former smoker	40 (53.3)	125 (49.0)	0.511	40 (53.3)	125 (49.0)	0.511	26 (52.0)	139 (49.6)	0.759
Current smoker	20 (26.7)	52 (20.4)	0.247	20 (26.7)	52 (20.4)	0.247	12 (24.0)	60 (21.4)	0.685
Cigarette smoker pack-years	30.6 (24.7)	24.4 (24.8)	0.041*	31.2 (28.0)	24.4 (23.8)	0.082	30.1 (29.8)	25.1 (24.0)	0.365
Hypertension, n (%)	36 (48.0)	68 (26.7)	<0.001*	31 (43.7)	73 (28.2)	0.013*	20 (40.0)	84 (30.0)	0.161

Doctor diagnosed COPD, n (%)	40 (53.3)	87 (34.1)	0.003*	38 (53.5)	89 (34.4)	0.003*	27 (54.0)	100 (35.7)	0.014*
Asthma, n (%)	35 (46.7)	104 (40.8)	0.364	32 (45.1)	107 (41.3)	0.57	28 (56.0)	111 (39.6)	0.031*
Any respiratory medications, n (%)	41 (54.7)	123 (48.2)	0.327	39 (54.9)	125 (48.3)	0.32	32 (64.0)	132 (47.1)	0.028*
<b>Lung function at rest</b>									
FEV <sub>1</sub> , %pred	65.7 (18.8)	78.5 (16.5)	<0.001*	66.8 (17.6)	78.0 (17.2)	<0.001*	65.6 (18.8)	77.3 (17.1)	<0.001*
FVC, %pred	95.5 (21.0)	104.0 (18.4)	<0.001*	96.6 (21.0)	103.6 (18.7)	0.007*	93.6 (21.5)	103.6 (18.6)	<0.001*
FEV1/FVC, %	53.1 (10.4)	58.5 (6.9)	<0.001*	53.3 (9.6)	58.3 (7.3)	<0.001*	54.1 (9.9)	57.8 (7.7)	0.009*
TLC, %pred	108.7 (16.2)	110.6 (15.0)	0.379	108.9 (16.2)	110.5 (15.0)	0.488	109.5 (17.0)	110.3 (15.0)	0.76
IC, %pred	88.4 (21.5)	96.9 (22.7)	0.002*	90.2 (21.6)	96.3 (22.8)	0.025*	91.9 (22.3)	95.6 (22.8)	0.19
D <sub>L</sub> CO, %pred	74.8 (20.9)	91.6 (22.9)	<0.001*	77.0 (22.8)	90.9 (22.8)	<0.001*	82.2 (22.4)	88.9 (23.6)	0.072
<b>Self-reported outcomes</b>									
MRC breathlessness rating	2.2 (0.9)	1.5 (0.6)	<0.001*	2.0 (0.9)	1.6 (0.6)	<0.001*	2.2 (0.9)	1.6 (0.6)	<0.001*
MRC breathlessness rating ≥ 3, n (%)	20 (26.7)	13 (5.1)	<0.001*	16 (22.5)	17 (6.6)	<0.001*	14 (28.0)	19 (6.8)	<0.001*
HADS anxiety	4.4 (3.4)	3.8 (2.9)	0.313	4.5 (3.2)	3.8 (3.0)	0.141	4.5 (3.3)	3.9 (3.0)	0.23




score									
HADS depression score	3.9 (3.4)	2.6 (2.4)	<0.001*	3.8 (3.4)	2.6 (2.4)	0.003*	3.8 (3.4)	2.7 (2.5)	0.033*
CAT total score	12.9 (7.8)	7.7 (6.0)	<0.001*	12.4 (8.1)	7.9 (6.1)	<0.001*	12.1 (8.2)	8.3 (6.4)	0.002*
CAT total $\geq$ 10, n (%)	47 (62.7)	83 (32.5)	<0.001*	45 (63.4)	85 (32.8)	<0.001*	30 (60.0)	100 (35.7)	0.001*
SGRQ total score	30.5 (18.1)	15.0 (13.6)	<0.001*	28.2 (19.5)	15.9 (13.9)	<0.001*	29.2 (19.5)	16.6 (14.6)	<0.001*
CHAMPS moderate and greater intensity, Caloric expenditure per week (KC)	1658.7 (1943.0)	2528.6 (2552.9)	0.002*	1435.2 (1733.1)	2576.4 (2563.7)	<0.001*	1602.2 (2047.8)	2461.0 (2498.6)	0.005*
CHAMPS all activities, Caloric expenditure per week (KC)	3269.6 (2556.9)	4336.2 (3060.5)	0.003*	3009.3 (2249.4)	4391.1 (3093.1)	<0.001*	3326.6 (2572.8)	4230.8 (3034.9)	0.025*
<b>CPET parameter at peak exercise</b>									
Power output, %pred	66.9 (19.0)	85.7 (25.2)	<0.001*	73.3 (23.0)	83.7 (25.3)	0.002*	76.0 (27.3)	82.4 (24.7)	0.061
V'O <sub>2</sub> , %pred	71.4 (19.7)	86.1 (23.0)	<0.001*	70.6 (20.5)	86.1 (22.7)	<0.001*	74.5 (24.5)	84.2 (22.5)	0.002*

$V'_E$ , %pred	75.1 (20.1)	86.0 (25.4)	<0.001*	75.5 (21.6)	85.7 (25.1)	0.002*	71.4 (21.8)	85.7 (24.6)	<0.001*
Nadir $V'_E/V'CO_2$	34.2 (7.5)	31.3 (6.4)	0.005*	34.2 (7.3)	31.4 (6.5)	0.001*	32.4 (7.0)	31.9 (6.7)	0.892
Nadir $V'_E/V'CO_2 > 34$ , n (%)	32 (42.7)	68 (26.8)	0.010*	32 (45.1)	68 (26.4)	0.003*	15 (30.0)	85 (30.5)	1.000
Nadir $V'_E/V'CO_2 > ULN$ , n (%)	25 (33.3)	51 (20.1)	0.020*	25 (35.2)	51 (19.8)	0.010*	13 (26.0)	63 (22.6)	0.588
$V_T\%IC/V'_E$	1.66 (0.62)	1.34 (0.48)	<0.001*	1.68 (0.62)	1.34 (0.48)	<0.001*	1.83 (0.67)	1.34 (0.47)	<0.001*
EILV%TLC/ $V'_E$	2.14 (0.83)	1.70 (0.66)	<0.001*	2.19 (0.85)	1.70 (0.65)	<0.001*	2.39 (0.91)	1.70 (0.63)	<0.001*
$\Delta IC$ (L)	-0.27 (0.38)	-0.21 (0.39)	0.214	-0.26 (0.39)	-0.21 (0.39)	0.392	-0.25 (0.42)	-0.22 (0.38)	0.641
$\Delta IC/V'_E$	-0.007 (0.010)	-0.004 (0.008)	0.053	-0.006 (0.012)	-0.004 (0.007)	0.058	-0.006 (0.014)	-0.004 (0.007)	0.150
Decrease in IC of > 0.15L from pre-exercise baseline to peak exercise, n (%)	45 (60.8)	128 (54.5)	0.351	42 (61.8)	131 (54.4)	0.333	29 (59.2)	144 (55.4)	0.642

Data presented as mean (standard deviation) unless otherwise specified. *Abbreviations:* see Table 1.

## FIGURES

**Figure 1.** Participant flow chart



**Figure 2. Outcomes by the probability of breathlessness normality, where a lower probability reflects more abnormal breathlessness.** The probability was calculated using normative reference equations of the breathlessness intensity response during cycle cardiopulmonary exercise testing (CPET), in relation to power output (W), oxygen uptake ( $\dot{V}O_2$ ), and minute ventilation ( $\dot{V}'_E$ ) at peak exercise. People with a lower probability of breathlessness normality (more abnormal breathlessness) generally had worse outcomes including lung function, self-reported symptom burden and physical activity, health-related quality of life, exercise capacity, and developing more physiological abnormalities during the CPET.

